Abstract
Background
Survival outcomes for childhood cancers have significantly improved. As more children are now surviving into adulthood, knowledge of the long-term effects of childhood cancer treatments has become the focus of research.
Aim
To determine what is known about the incidence of renal function impairment in childhood cancer survivors and to determine what is known about risk factors for developing renal function impairment following childhood cancer treatment.
Methods
A comprehensive literature search was preformed to identify studies that investigated renal dysfunction in patients who were diagnosed with childhood cancer and treated with potentially nephrotoxic chemotherapeutic agents. Potentially nephrotoxic chemotherapeutic agents identified in the selection criteria include ifosfamide, cisplatin, carboplatin and methotrexate.
Results
15 papers met the inclusion criteria. Renal function impairment was reported in 15 of 15 studies included in this literature review. The incidence of ifosfamide induced nephrotoxicity varied from 1 to 50 %. This variation may be due to the heterogeneity of reported outcome measurements. Treatment with cisplatin and carboplatin was associated with hypomagnesemia. The prevalence of hypomagnesemia varied from 7 to 29 %. This variation may be due to diversity of treatment protocols. The incidence of renal dysfunction following treatment with methotrexate was reported as 1.8 % and completely reversible.
Conclusion
As more childhood cancer survivors are reaching adulthood, a new niche of cancer research has emerged. Researchers are now investigating the late effects due to cytotoxic treatments. Renal function impairment is a potential late effect of treatment with nephrotoxic chemotherapeutic agents including ifosfamide, cisplatin, carboplatin and methotrexate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brock PR, Koliouskas DE, Barratt TM et al (1991) Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 118(4):531–534
English MW, Skinner R, Pearson AD et al (1999) Dose-related nephrotoxicity of carboplatin in children. Br J Cancer 81(2):336–341
Fels LM, Bokemeyer C, van Rhee J et al (1996) Evaluation of late nephrotoxicity in long-term survivors of Hodgkin’s disease. Oncology 53(1):73–78
Grönroos MH, Jahnukainen T, Möttönen M et al (2008) Long-term follow-up of renal function after high-dose methotrexate treatment in children. Pediatr Blood Cancer 51(4):535–539
Jones DP, Spunt SL, Green D et al (2008) Renal late effects in patients treated for cancer in childhood: a report from the Children’s Oncology Group. Pediatr Blood Cancer 51(6):724–731
Lajer H, Daugaard G (1999) Cisplatin and hypomagnesemia. Cancer Treat Rev 24:47–58
Langer T, Stöhr W, Bielack S et al (2004) Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer 42(4):373–379
Loebstein R, Atanackovic G, Bishai R et al (1999) Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 39(5):454–461
National Cancer Registry Ireland (2014) Cancer Trends No. 23. Childhood cancers. http://www.ncri.ie/publications/cancer-trends-and-projections/cancer-trends-childhood-cancer. Accessed 9 Aug 2015
Rossi R, Pleyer J, Schäfers P et al (1999) Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med Pediatr Oncol 32(3):177–182
Skinner R (2003) Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 41(3):190–197
Skinner R, Cotterill SJ, Stevens MC (2000) Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children’s Cancer Study Group. Br J Cancer 82(10):1636–1645
Skinner R, Parry A, Price L et al (2009) Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer 45:3213–3219
Skinner R, Sharkey IM, Pearson AD et al (1993) Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11(1):173–190
Sporn MB (1996) The war on cancer. Lancet 347(9012):1377–1381
Stöhr W, Paulides M, Bielack S et al (2007) Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 48(2):140–147
Stöhr W, Paulides M, Bielack S et al (2007) Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatr Blood Cancer 48(4):447–452
von der Weid NX, Erni BM, Mamie C et al (1999) Cisplatin therapy in childhood: renal follow up 3 years or more after treatment. Swiss Pediatric Oncology Group. Nephrol Dial Transplant 14(6):1441–1444
Yu AS (2015) Evaluation and treatment of hypomagnesaemia. Up to date. http://www.uptodate.com. Accessed 16 Dec 2015
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
O’Sullivan, D. Late effects of chemotherapeutic agents on renal function in childhood cancer survivors: a review of the literature. Ir J Med Sci 186, 49–55 (2017). https://doi.org/10.1007/s11845-016-1473-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-016-1473-z